Virax Biolabs Group Limited Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Cover
- Document and Entity Information
Financial Statements
Notes to Financial Statements
Accounting Policies
- Summary of Significant Accounting Policies (Policies)
Notes Tables
Notes Details

Note Payable

Note Payable	12 Months Ended
Mar. 31, 2023
Borrowings [abstract]
Note Payable	Note 10 — Note Payable On July 1, 2022, the Company entered into a note payable with a third party for the purpose of financing its Directors and Officers insurance policy. The unsecured loan at inception was $487,500 for a period of ten months with a 2.5% fixed interest rate. The balance of the note payable at March 31, 2023 is $146,250. There was no note payable at March 31, 2022.

Note Payable

12 Months Ended

Mar. 31, 2023

Borrowings [abstract]

Note Payable

Note 10 — Note Payable

On July 1, 2022, the Company entered into a note payable with a third party for the purpose of financing its Directors and Officers insurance policy. The unsecured loan at inception was $487,500 for a period of ten months with a 2.5% fixed interest rate. The balance of the note payable at March 31, 2023 is $146,250. There was no note payable at March 31, 2022.